ScholarIQanswers from OpenAlex & ORCID
Jordi Rodón
ResearcherPublications, citations & collaboration network
Jordi Rodón is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jordi Rodón have?
ScholarIQindexed works
Jordi Rodón has 909 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jordi Rodón have?
ScholarIQcitation count
Jordi Rodón has 21,306 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jordi Rodón?
ScholarIQh-index
Jordi Rodón has an h-index of 69 in OpenAlex.
What is the i10-index of Jordi Rodón?
ScholarIQi10-index
Jordi Rodón has an i10-index of 204 in OpenAlex.
What is the ORCID of Jordi Rodón?
ScholarIQorcid
The ORCID for Jordi Rodón is on the source record.
What is the OpenAlex record for Jordi Rodón?
ScholarIQopenalex
The OpenAlex for Jordi Rodón is on the source record.
What are the most-cited papers on Jordi Rodón?
ScholarIQmost cited works
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodón, Jean‐Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia M. Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña, Yohann Loriot, Mohammad Afshar, Vincent A. Miller, Fanny Wunder, Catherine Bresson, Jean-François Martini, Jacques Raynaud, John Mendelsohn, Gerald Batist, Amir Onn, Josep Tabernero, Richard L. Schilsky, Vladimir Lazar, J. Jack Lee, Razelle Kurzrock
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao, Daniel E. Spratt, Nerissa T. Viola, Pau Castel, Gerard Minuesa, Natasha Morse, Jordi Rodón, Yasir H. Ibrahim, Javier Cortés, José Manuel Pérez-García, Patricia Galván, Judit Grueso, Marta Guzmán, John A. Katzenellenbogen, Michael G. Kharas, Jason S. Lewis, Maura N. Dickler, Violeta Serra, Neal Rosen, Sarat Chandarlapaty, Maurizio Scaltriti, José Baselga
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer
Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson